Deals In Depth: May 2019
Executive Summary
As it plans to focus on core therapy areas following the Shire acquisition, Takeda divested dry eye drug Xiidra to Novartis for up to $5.3bn. 3M bought wound care firm Acelity from an investor consortium led by Apax partners for $6.7bn. Both pharma and device financing was up over the previous month, with strong showings from debt offerings.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.